10-Q: Biotricity Inc. Reports Increased Revenue and Reduced Operating Expenses in Q3 2025

Biotricity Inc. announces revenue growth and reduced operating expenses for the quarter ended December 31, 2024, signaling progress towards profitability.

Summary

• Biotricity Inc. reported a revenue increase of 13.5% to $10.1 million for the nine months ended December 31, 2024, compared to $8.9 million in the same period last year.
• Technology fee revenue rose by 14.3% to $9.5 million, comprising 93.9% of total revenue.
• Gross profit margin improved to 75.2% from 68.5% due to better margins on technology fees and device sales.
• Operating expenses decreased by 24.1% to $7.6 million, reflecting cost control measures.
• Research and development expenses decreased to $1.6 million from $1.9 million.
• The company experienced a net loss of $6.5 million before income taxes.
• EBITDA improved by 62.9% compared to the prior year, and adjusted EBITDA showed a significant improvement, reducing the negative figure by approximately $1 million.
• The company had a working capital deficit of $16.3 million as of December 31, 2024.
• The company is actively selling in 35 U.S. states as of December 31, 2024.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there are positive trends in revenue growth, gross margin improvement, and cost reduction, the company still faces significant challenges related to its financial position and ability to continue as a going concern. The need for additional funding and the recent delisting from Nasdaq add to the uncertainty.

Positives

• Revenue growth of 13.5% indicates increasing market adoption of Biotricity's solutions.
• Improved gross profit margin suggests better operational efficiency and pricing strategies.
• Significant reduction in operating expenses demonstrates effective cost management.
• Growth in technology fee revenue highlights the recurring nature of the business model.
• Improvement in EBITDA and adjusted EBITDA shows progress towards profitability.
• The company is actively selling in 35 U.S. states as of December 31, 2024.

Negatives

• The company continues to operate with a working capital deficit of $16.3 million.
• The company experienced a net loss of $6.5 million before income taxes.
• The company has an accumulated deficit of $137.4 million.

Risks

• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.
• The company needs to secure additional funding to sustain operations.
• Failure to raise capital could compromise the company's ability to execute its business plan.
• The company's common stock was delisted from The Nasdaq Capital Market and is now listed on the OTCQB.

Future Outlook

Management anticipates the Company will continue on its revenue growth trajectory and improve its liquidity through continued business development and after additional equity and debt capitalization of the Company.

Industry Context

The report highlights the increasing importance of telemedicine and remote patient monitoring technologies, aligning with broader industry trends accelerated by the COVID-19 pandemic. The company's focus on AI-driven solutions also positions it to capitalize on the growing healthcare AI market.

Comparison to Industry Standards

• The report does not provide specific comparisons to industry standards or competitors.
• However, the focus on recurring technology fee revenue and the insourcing business model are strategies that aim to improve market penetration and reduce operating overhead, which are common goals in the medical technology industry.
• The company's development of AI-driven solutions aligns with the industry's increasing focus on leveraging data and technology to improve patient care and outcomes.

Related Party Transactions

• Trade and other payables and accrued liabilities as at December 31, 2024 and March 31, 2024 included $ 653,623 and $ 1,303,424 , respectively, due to two shareholders, who are executives of the Company.

Stakeholder Impact

• Shareholders face potential dilution from future financing activities.
• Employees may be affected by cost control measures and the company's ability to secure funding.
• Customers may benefit from the company's continued development of innovative remote monitoring solutions.
• Creditors face increased risk due to the company's financial challenges and need for additional funding.

Next Steps

• The company intends to continue to provide improved care to patients that may otherwise elect not to go to medical facilities and continue to provide economic benefits and cost savings to healthcare service providers and payers that reimburse.
• The company plans to grow its sales force in order to address new markets and achieve sales penetration in the markets currently served.
• The company intends to continue to develop a telemedicine platform, with capabilities of real-time streaming of medical devices.

Key Dates

Keywords

Biotricity, revenue, EBITDA, remote monitoring, financial results, operating expenses, technology fees, gross margin, net loss, financial statements